Clinical trials: Prostate Cancer Recurrence After Radical Prostatectomy, active
Prostate Cancer
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
This is a prospective study to determine if the adjuvant use of Curcumin improves recurrence-free survival.
- Trial name
- NCT02064673
- Testing
- Curcumin
- Where
- United States
- Volunteers
- 650 people
- Sponsor
- yair lotan
Prostate Cancer (Adenocarcinoma)
Predictive Factors for 10-year Biochemical Recurrence and Urinary Continence Following Robot-assisted Radical Prostatectomy for Prostate Cancer
The aim of the present project is to evaluate long-term oncological and functional treatment outcomes, as well as patient satisfaction, ten years after radical prostatectomy in patients initially enrolled in CPRRP study.
- Trial name
- NCT07439913
- Testing
- Radical prostatectomy
- Where
- Slovakia
- Volunteers
- 120 people
- Sponsor
- F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
Prostate Cancer, Biochemical Recurrence
Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Failure After Prostatectomy
Patients with a biochemical recurrence after radical prostatectomy for moderate- or high- risk prostate cancer are randomly assigned to hypofractionated, accelerated high dose radiation therapy group (65 Gy, 26 fractions) and a…
- Conditions
- Prostate Cancer, Biochemical Recurrence, Radiation, Hypofractionation
- Trial name
- SHARE (NCT03920033)
- Testing
- Salvage radiation therapy
- Where
- 2 sites in South Korea
- Volunteers
- 288 people
- Sponsor
- Asan Medical Center
Prostate Cancer
Long-term Better Than Short-term ADT With Salvage RT
A randomized, multicenter, prospective PHASE II trial to assess the effect of short- versus long-term adjuvant ADT with high dose salvage radiotherapy on distant metastasis free survival in case of biochemical relapse (BR) after…
- Trial name
- LOBSTER (NCT04242017)
- Testing
- Triptoreline
- Where
- 3 sites in Belgium
- Volunteers
- 394 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Recurrent Prostate Cancer
Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy
The main objective of the trial is to explore the efficacy and safety of combining short-term androgen deprivation therapy (ADT) over 6 months to focal ultrahypofractionated salvage radiotherapy (SRT) delivered in 5 fractions to…
- Trial name
- HypoFocal SRT (NCT05746806)
- Testing
- Ultrahypofractionated salvage radiotherapy to a local recurrence after radical prostatectomy, Androgen deprivation therapy
- Where
- 5 sites in Switzerland
- Volunteers
- 36 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Prostate Cancer
Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
All men following Radical Prostatectomy (RP) at NYU Langone Health undergo routine prostate specific antigen (PSA) testing in order to identify disease recurrence.
- Trial name
- NCT05678322
- Testing
- 18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent, PET MRI Imaging
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- NYU Langone Health
Prostate
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Olaparib has demonstrated preliminary efficacy in metastatic castration-resistant prostate cancer. In a trial of 49 evaluable patients treated with olaparib, 11 / 49 experienced a PSA response, and every patient with a…
- Trial name
- NCT03047135
- Testing
- Olaparib
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer (Post Prostatectomy)
Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy
Prostate cancer patients with high-risk features who undergo radical prostatectomy (RP) are at a significant risk of biochemical recurrence (BCR) and disease progression.
- Trial name
- ARMOR (NCT07711314)
- Testing
- Rezvilutamide Tablets
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer, Biochemical Recurrence
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or SRT combination with ADT in prostate cancer patients with biochemical…
- Trial name
- NCT06305832
- Testing
- Rezvilutamide, Androgen deprivation therapy (ADT), SRT
- Where
- 2 sites in China
- Volunteers
- 102 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Recurrent Prostate Cancer After Surgery
This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.
There is significant, proven use of radiation for recurrent prostate cancer after surgical resection. This treatment typically is delivered over seven and a half weeks of daily treatments, presenting a burden to patients and the…
- Trial name
- DASBRT-RPC (NCT05946824)
- Testing
- Daily-adaptive Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Prostate Cancer, Biochemical Recurrence
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or rezvilutamide in combination with ADT in prostate cancer patients with…
- Trial name
- NCT05753566
- Testing
- Rezvilutamide, Androgen deprivation therapy (ADT), SRT
- Where
- 2 sites in China
- Volunteers
- 96 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
This phase III trial tests the side effects of stereotactic body radiation therapy (SBRT) compared to hypofractionated radiotherapy for treating patients with prostate adenocarcinoma that has come back after a period of…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Recurrent Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
- Trial name
- NCT06205316
- Testing
- Antiandrogen Therapy, Biospecimen Collection, Hypofractionated Radiation Therapy
- Where
- 6 sites in United States
- Volunteers
- 118 people
- Sponsor
- Mayo Clinic
Prostate Cancer, Biochemical Recurrence
Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)
ARES is a multicenter, single-arm, phase 2 trial to evaluate the efficacy and safety of ADT in combination with apalutamide as an adjuvant regimen for patients with high risk of recurrence after radical prostatectomy.
- Conditions
- Prostate Cancer, Biochemical Recurrence, High Risk
- Trial name
- ARES (NCT05778097)
- Testing
- Apalutamide 60mg Tab, Androgen deprivation therapy(ADT)
- Where
- 3 sites in China
- Volunteers
- 103 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Recurrent Prostate Carcinoma
Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy
This phase III trial studies how well Gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) positron emission tomography (PET)/computed tomography (CT) works in diagnosing participants with prostate cancer that has come back after…
- Trial name
- PSMA SRT (NCT03582774)
- Testing
- Best Practice, Computed Tomography, Gallium Ga 68-labeled PSMA-11
- Where
- 2 sites in United States
- Volunteers
- 193 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer, Prostatectomy
High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy
The goal of this observational study is to learn about the long-term effects of HDR Brachytherapy in men with isolated local relapses after radical prostatectomy.
- Conditions
- Prostate Cancer, Prostatectomy, Local Recurrence of Malignant Tumor of Prostate, Radiotherapy; Complications
- Trial name
- NCT06982469
- Testing
- Brachytherapy
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Prostate Cancer, Cancer Recurrence
PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy
After radical prostatectomy approximately 15-40% of men develop a biochemical recurrence (BR) within 5 years. The standard treatment of post-prostatectomy BR is salvage external beam radiation therapy (sEBRT).
- Trial name
- PERYTON (NCT04642027)
- Testing
- Conventional sEBRT, Hypofractionated sEBRT
- Where
- 13 sites in Netherlands
- Volunteers
- 538 people
- Sponsor
- University Medical Center Groningen
Prostate Cancer
Salvage Stereotactic Body Radiotherapy of the Prostate Bed for Biochemical Recurrence After Radical Prostatectomy.
This is a a randomized phase II/III trial comparing salvage SBRT with standard of care (SOC) regimens for patients with a persistent detectable PSA or biochemical progression during follow-up after radical prostatectomy.
- Trial name
- STEREOBED (NCT06523634)
- Testing
- Stereotactic body radiotherapy (SBRT), SOC RT
- Where
- 13 sites in Belgium
- Volunteers
- 284 people
- Sponsor
- Jules Bordet Institute
Prostate Cancer, Biochemical Recurrence
Predictors of BCR After RARP for Localized Prostate Cancer: A Retrospective Analysis
This retrospective study aims to identify predictive factors for biochemical recurrence (BCR) in patients with localized prostate cancer who underwent robot-assisted radical prostatectomy (RARP).
- Trial name
- NCT07682584
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Prostate Cancer
Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer
This study is the first prospective, randomized phase III clinical trial designed to evaluate whether ultrahypofractionated radiotherapy is non-inferior to conventionally moderately hypofractionated radiotherapy in terms of…
- Trial name
- NCT07500701
- Testing
- Moderate hypofractionated radiotherapy (Moderate-hypoRT), Ultra-hypofractionated radiotherapy (Ultra-hypoRT)
- Where
- South Korea
- Volunteers
- 270 people
- Sponsor
- Samsung Medical Center
Prostate Cancer
Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
Prostate cancer is the most common cancer in men and radical prostatectomy is the most frequent treatment for this disease. Unfortunately, approximately 40% of patients will develop recurrence after surgery, requiring additional…
- Trial name
- NCT05169112
- Testing
- Lupron Depot
- Where
- 3 sites in Canada
- Volunteers
- 72 people
- Sponsor
- Ottawa Hospital Research Institute